Loading...
Loading...
LXRX| Name | Value |
|---|---|
| Revenues | 26.6M |
| Cost of Revenue | 0.3M |
| Gross Profit | 26.2M |
| Operating Expense | 59.1M |
| Operating I/L | -32.7M |
| Other Income/Expense | -1.0M |
| Interest Income | 2.8M |
| Pretax | -33.8M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | -33.8M |
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of orally-delivered small molecule drug candidates. Its lead products include Sotagliflozin, which has completed Phase III clinical trials for the treatment of heart failure and type 1 diabetes, and LX9211, currently in Phase II clinical development for neuropathic pain treatment. The company generates revenue through strategic collaboration and license agreements with industry leaders such as Bristol-Myers Squibb Company and Genentech, Inc., leveraging its innovative drug pipeline to address unmet medical needs and drive commercial success.
